This trial will test a new strategy to prevent hepatitis B transmission from women to newborns in Africa.
2 Primary · 8 Secondary · Reporting Duration: 6-9 months of age
Experimental Treatment
Non-Treatment Group
450 Total Participants · 2 Treatment Groups
Primary Treatment: Tenofovir Disoproxil Fumarate · Has Placebo Group · Phase 3
Age 16 - 50 · Female Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: